KR950700062A - 신경병 치료에 있어서 4-아미노피리딘의 사용 - Google Patents

신경병 치료에 있어서 4-아미노피리딘의 사용

Info

Publication number
KR950700062A
KR950700062A KR1019940702838A KR19940702838A KR950700062A KR 950700062 A KR950700062 A KR 950700062A KR 1019940702838 A KR1019940702838 A KR 1019940702838A KR 19940702838 A KR19940702838 A KR 19940702838A KR 950700062 A KR950700062 A KR 950700062A
Authority
KR
South Korea
Prior art keywords
aminopyridine
treatment
spinal cord
commercial package
pct
Prior art date
Application number
KR1019940702838A
Other languages
English (en)
Other versions
KR100301415B1 (ko
Inventor
알. 한스보트 로버트
알. 브라이트 앤드류
Original Assignee
레이 위크숀
캐나디안 스파이날 리서치 오거니제이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레이 위크숀, 캐나디안 스파이날 리서치 오거니제이션 filed Critical 레이 위크숀
Publication of KR950700062A publication Critical patent/KR950700062A/ko
Application granted granted Critical
Publication of KR100301415B1 publication Critical patent/KR100301415B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

신경학적 상태를 치료하기 위한 4-아미노피리딘의 용도가 개시된다. 특히, 본 발명은 척수손상 환자를 치료하기 위한 4-아미노피리딘의 용도에 관한 것이다. 4-아미노피리딘은 척수손상환자에게 약 18내지 약 30mg의 투여량으로 투여될 경우 통증과 경련을 완화시킨다는 것이 발견되었다. 상기 결과는 상기 질환의 높은 빈도수와 척수손상 환자의 중추적 통증의 처치곤란한 성격을 감안할 때 매우 중요하다. 4-아미노피리딘은 감각능과 운동 조절을 증가시키는 데도 유용하다.

Description

신경병 치료에 있어서 4-아미노피리딘의 사용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 총투여량의 증가순으로 모든 피검자에 있어서 4-AP의 혈장레벨변화의 시간경로를 나타낸다. 대부분의 피검자는 장-시스템의 재순환(Entero-Systemic recirculation)을 나타내는, 측정된 용량레벨의 어느 정도의 진폭을 나타낸다. 4-AP 주입기간은 고체 바에 의해 표시된다. 그림 2는 투여된 4-아미노피리딘 총용량(In mg/kg)과 측정된 최대 혈장 레벨 사이의 상호관계를 나타내는 스캐터플롯(Scatterplot)이다. 관측된 관계(최소 스퀘어 리그레션)은 약 2시간 지나 각각 1mg/kg씩 주사되고 얻어진 최고 혈장 레벨은 약 0.27mg/l이다. 그림 3은 4-AP의 2차 비맹검투여에 따른 2 피검자(EB, GCh)에 기록된 4-AP의 혈장 레벨 그라프이다. 혈장 레벨은 두 환자 모두에게 48시간만에 탐지되는 최소 농도(C. 3ng/ml)이하였다. 그림 4는 2차 검사를 받은 두 피검자(GCh 와 EB)에 있어서 핀프릭(Pin-Prick)감각의 신경학적 스코어의 변화의 연속을 나타내는 히스토그램이다. 좌측과 우측의 평균 스코어는 C5와 S1사이의 테스트된 피판(dermatome)을 나타낸다. 양 피검자의 지각 스코어의 최대 개선은 약물투여후 24시간만에 얻어졌다. 72시간(GHh)에 관찰된 환자는 약물투여전 상태로 완전히 돌아왔다.

Claims (12)

  1. 신경계에 영향을 주는 상태의 치료를 위한 4-아미노피리딘의 용도.
  2. 제1항에 있어서, 신경학적 상태가 척수 손상인 4-아미노피리딘의 용도.
  3. 통증 완화를 위한 4-아미노피리딘의 용도.
  4. 제3항에 있어서, 척수손상된 환자의 통증 완화를 위한 4-아미노피리딘의 용도.
  5. 경련 완화를 위한 4-아미노피리딘의 용도.
  6. 제5항에 있어서, 척수손상된 환자의 경련을 완화시키기 위한 4-아미노피리딘의 용도.
  7. 제1 내지 6항중 어느 한 항에 있어서, 4-아미노피리딘이 약 15 내지 약 30mg의 투여량으로 사용되는 용도.
  8. 제7항에 있어서, 4-아미노피리딘이 정맥내 투여되는 용도.
  9. 척수손상 환자를 치료하기 위한 4-아미노피리딘의 용도에 대한 지시와 함께 활성성분으로서 4-아미노피리딘을 함유하는 상업적 포장체.
  10. 경련 치료를 위한 4-아미노피리딘의 용도에 대한 지시와 함께 활성성분으로서 4-아미노피리딘을 함유하는 상업적 포장체.
  11. 통증 치료를 위한 4-아미노피리딘의 용도에 대한 지시와 함께 활성성분으로서 4-아미노피리딘을 함유하는 상업적 포장체.
  12. 제9 내지 11항중 어느 한 항에 있어서, 4-아미노피리딘이 약 15 내지 약 30mg 존재하는 상업적 포장체.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940702838A 1992-12-18 1993-12-20 신경병치료에있어서4-아미노피리딘의사용 KR100301415B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2,085,785 1992-12-18
CA002085785A CA2085785C (en) 1992-12-18 1992-12-18 The use of 4-aminopyridine in the treatment of a neurological condition
CA2085785 1992-12-18
PCT/CA1993/000554 WO1994014439A1 (en) 1992-12-18 1993-12-20 The use of 4-aminopyridine in the treatment of a neurological condition

Publications (2)

Publication Number Publication Date
KR950700062A true KR950700062A (ko) 1995-01-16
KR100301415B1 KR100301415B1 (ko) 2001-11-22

Family

ID=4150879

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702838A KR100301415B1 (ko) 1992-12-18 1993-12-20 신경병치료에있어서4-아미노피리딘의사용

Country Status (19)

Country Link
US (1) US5545648A (ko)
EP (1) EP0626848B1 (ko)
JP (1) JP3474569B2 (ko)
KR (1) KR100301415B1 (ko)
AT (1) ATE241981T1 (ko)
AU (1) AU676251B2 (ko)
BG (1) BG62272B1 (ko)
BR (1) BR9305909A (ko)
CA (1) CA2085785C (ko)
CZ (1) CZ284441B6 (ko)
DE (1) DE69333014T2 (ko)
ES (1) ES2199957T3 (ko)
FI (1) FI943765A (ko)
HU (1) HU219583B (ko)
NO (2) NO308644B1 (ko)
NZ (1) NZ258844A (ko)
RU (1) RU2160590C2 (ko)
SK (1) SK280922B6 (ko)
WO (1) WO1994014439A1 (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
JPH09315972A (ja) * 1996-03-22 1997-12-09 Chugai Pharmaceut Co Ltd 脊髄損傷治療剤
WO1999004705A1 (en) 1997-07-25 1999-02-04 Tsui Ban C H Devices, systems and methods for determining proper placement of epidural catheters
US7582680B1 (en) 1998-11-12 2009-09-01 Purdue Research Foundation Methods and compositions for treating mammalian spinal cord injuries
WO2000047210A1 (en) * 1999-02-09 2000-08-17 Uab Research Foundation Use of 4-amino pyridine for treatment of peripheral neuropathies
NO324322B1 (no) 2001-02-26 2007-09-24 Dynea Oy Anvendelse av herder samt fremgangsmate ved liming
CA2445612C (en) 2001-04-24 2011-10-25 Purdue Research Foundation Methods and compositions for treating mammalian nerve tissue injuries
US20040047843A1 (en) * 2002-02-12 2004-03-11 Uab Research Foundation Method for spinal cord reconnection
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
WO2004052291A2 (en) * 2002-12-06 2004-06-24 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
JP4533590B2 (ja) * 2003-02-28 2010-09-01 ファイザー株式会社 脊髄損傷患者における疼痛又は痙性軽減用医薬組成物
US20050192321A1 (en) * 2003-09-15 2005-09-01 Meythaler Jay M. Treatment of neuropathy with rapid release aminopyridine
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20130030025A1 (en) * 2011-01-28 2013-01-31 Wessel Thomas C Use of potassium channel blockers to treat cerebral palsy
US8924325B1 (en) * 2011-02-08 2014-12-30 Lockheed Martin Corporation Computerized target hostility determination and countermeasure
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508715A (en) * 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
WO1989009600A1 (en) * 1988-04-08 1989-10-19 Massachusetts Institute Of Technology Method and composition for treating neurological disorders
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases

Also Published As

Publication number Publication date
BR9305909A (pt) 1997-10-21
EP0626848B1 (en) 2003-06-04
AU5691194A (en) 1994-07-19
ES2199957T3 (es) 2004-03-01
HUT68171A (en) 1995-05-29
NO308644B1 (no) 2000-10-09
FI943765A (fi) 1994-10-14
US5545648A (en) 1996-08-13
ATE241981T1 (de) 2003-06-15
CA2085785C (en) 2005-03-15
DE69333014T2 (de) 2004-05-06
NZ258844A (en) 1997-04-24
NO943049L (no) 1994-10-17
JPH08504772A (ja) 1996-05-21
NO2012003I2 (no) 2013-02-18
WO1994014439A1 (en) 1994-07-07
KR100301415B1 (ko) 2001-11-22
EP0626848A1 (en) 1994-12-07
NO943049D0 (no) 1994-08-17
HU9402647D0 (en) 1994-11-28
RU2160590C2 (ru) 2000-12-20
SK280922B6 (sk) 2000-09-12
CZ225494A3 (en) 1995-03-15
AU676251B2 (en) 1997-03-06
BG99047A (bg) 1995-06-30
RU94041207A (ru) 1996-06-20
BG62272B1 (bg) 1999-07-30
DE69333014D1 (de) 2003-07-10
SK96994A3 (en) 1995-04-12
CA2085785A1 (en) 1994-06-19
JP3474569B2 (ja) 2003-12-08
FI943765A0 (fi) 1994-08-16
HU219583B (hu) 2001-05-28
NO2012003I1 (no) 2012-02-13
CZ284441B6 (cs) 1998-11-11

Similar Documents

Publication Publication Date Title
Aho et al. Effect of intravenously administered dexmedetomidine on pain after laparoscopic tubal ligation
KR950700062A (ko) 신경병 치료에 있어서 4-아미노피리딘의 사용
Avramov et al. The comparative effects of methohexital, propofol, and etomidate for electroconvulsive therapy
Crolle et al. Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation
Lee et al. Comparison of a bupivacaine-clonidine mixture with plain bupivacaine for caudal analgesia in children
Abber et al. Priapism induced by chlorpromazine and trazodone: mechanism of action
Girgin et al. Intrathecal morphine in anesthesia for cesarean delivery: dose-response relationship for combinations of low-dose intrathecal morphine and spinal bupivacaine
Brazeau et al. Current perspectives on pain upon injection of drugs
Moulin Pain in central and peripheral demyelinating disorders: Multiple sclerosis and Guillain-Barre syndrome
Faiz et al. Anesthetic effects of adding intrathecal neostigmine or magnesium sulphate to bupivacaine in patients under lower extremities surgeries
George et al. Thoracic epidural infusion for postoperative pain relief following abdominal aortic surgery: bupivacaine, fentanyl or a mixture of both?
Guinn et al. Antagonism of intravenous cocaine lethality in nonhuman primates
Baad-Hansen et al. Differential effect of intravenous S-ketamine and fentanyl on atypical odontalgia and capsaicin-evoked pain
Gatt et al. Preemptive analgesia: its role and efficacy in anterior cruciate ligament reconstruction
Somrat et al. Optimal dose of nalbuphine for treatment of intrathecal‐morphine induced pruritus after caesarean section
Begemann et al. Treatment of refractory complex‐partial status epilepticus with propofol: case report
Robertson et al. Treatment of post herpetic neuralgia in the elderly
Weissenbacher et al. Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study
Vaida et al. The influence of preemptive spinal anesthesia on postoperative pain
EP0706395B1 (en) Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade
Raymond Fink Acute and chronic toxicity of local anaesthetics
Torbiner et al. Effect of midazolam pretreatment on the intravenous toxicity of lidocaine with and without epinephrine in rats
Wilkerson Cardiovascular toxicity of cocaine
AU2469399A (en) Methods of decreasing or preventing pain using spicamycin or derivatives thereof
Briggs et al. Morphine: continuous intravenous infusion versus intramuscular injections for postoperative pain relief

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120607

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20130611

Year of fee payment: 13

EXPY Expiration of term